adj ep shi consensu below-the-lin
factor dplo adj ep fell short reflect better profit
off-set factor line importantli maintain
top-line ebitda guidanc adjust ep
reflect miss below-the-lin item
make chang oper assumpt
revenu light profit ahead revenu shi plan
lower specialti experi vs estimate includ rise
organ growth volum vs estimate pbm revenu
contribut claim volum larg line importantli profit
exceed plan ebitda margin rise bp y/i better
plan help acquisit expedit pbm synergi manufactur
price increas off-set weaker specialti gross profit restat flow
million help facilit de-lever effort
reiter neutral dplo share deterior recent
high june vs rise concern potenti evolv
drug pricing/reb paradigm continu remain posit dispos
toward recent pbm endeavor synergi run ahead plan
view segment help drive new busi win
increment opportun potenti vertic integr competit
landscap note traction middle-market account date term
rebat note indic commerci custom shift
practic despit washington rhetor highlight commentari
expert call expert insight suggest new revenu profit stream
could offset rebate-fre market risk includ shift demand
reimburs integr headwind dplo boston ndr
pleas contact team relev sale repres detail
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
diplomat pharmaci independ specialti pharmaci
dispens pharmaceut patient complex chronic
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
grey sky scenario predic unexpect
slowdown specialti pharmaceut industri
regulatory/reimburs shift integr miscu
 close
blue sky scenario predic acceler
integr recent acquir pbm accompani earlier
expect execut cost synergi cross-sel
acceler de-lever allow dplo resum acquisit
strategi earlier expect strategi mind potenti
diversifi suppli chain acquir could like
second full quarter contribut newli creat pbm entiti castiarx
dplo post revenu growth revenu specialti segment incl
servic data consult previous report separ total million
pbm sale total million larg line view million regard
legaci specialti pharmaci excl servic data consult estim organ
revenu growth exclud acquisit contribut million
quarter start lap prior year headwind hep contract shift
perform repres encourag improv estim rise
declin cours
conjunct dplo maintain revenu outlook million
incorpor pbm contribut importantli reiter oper guidanc
includ adj ebitda rang million adjust ep assumpt
lower larg line item
compani data credit suiss estim bloomberg profession servic
dplo gener million cash quarter vs million ttm
cash convers cycl decreas one day nine day better dio experi
importantli relat capit deploy focu near term de-lever
compani target net leverag ratio debt paydown
total million estim pro forma ttm net leverag stand
total debt stand million includ conting consider
broadli expect dplo begin realiz benefit diversifi
differenti pharmaci solut follow recent pbm
transact notabl shift strategi compani new pbm focu repres
logic evolut view help drive new busi win may
disadvantag comprehens pbm offer
evidenc contract loss past year still leverag uniqu access
product limit distribut drug panel specialti infus offer manufactur
servic comprehens pbm solut offer new avenu growth
view
longer term follow near term focu de-lever expect
clear path dplo continu scale pbm offer longer term
continu previou manag note capit deploy form pbm
acquisit product use capit move forward supplement
cross-sel opportun across current custom base initi synergi
recent pbm deal materi meaning beyond
remind dplo name brian griffin perman ceo effect june griffin
replac former interim ceo jeff park remain member dplo board
director bod follow retir co-found phil hagerman announc
januari join dplo extens pbm industri experi includ
recent name ceo ingeniorx new pbm subsidiari three year
presid commerci specialti busi divis year
lead pbm medco later acquir express script esrx outperform
also join compani bod chairman
appoint respect industri veteran well-receiv investor
bring search hagerman replac close reiter compani
recent initi lt pbm strategi accord manag team
desir becom public compani ceo transit understand
although initi surpris interim ceo jeff park resign see note
manag meet dplo race boston encourag
wealth industri experi broadli evolv strateg vision
compet new manag extens pbm experi view dplo
better posit expand specialti pharmaci unit profit
earn outlook valuat
forecast revenu grow larg driven contribut recent
acquir pbm ldi np total estim million gross revenu
full year forecast ebitda margin expans bp drive ebitda
growth help higher margin contribut recent acquisit lead ep
y/i increas
forecast revenu grow forecast ebitda margin degrad
bp drive ebitda growth ep grow help
expect focu de-lever cours
compani mention price
